trending Market Intelligence /marketintelligence/en/news-insights/trending/0W2rFjTOUblr2ynXDm4Ehw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

OncoSec undertakes 1-for-10 reverse stock split

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


OncoSec undertakes 1-for-10 reverse stock split

Pennington, N.J.-based cancer drug developer OncoSec Medical Inc.'s board approved a 1-for-10 reverse stock split of its common stock, effective May 20.

The move reduced the company's issued and outstanding common shares to about 7 million from approximately 70 million.

OncoSec's shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market under the ticker ONCS, effective May 21.